John Aey, MD
Ophthalmology · Poland, OHNPI 1316949803
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,301 of the $7,601 with a category attached, or 82.9%. 22 manufacturers reported payments, led by AbbVie at 41.8% of the total.
Across 286 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Alcon$1K
- NEW World Medical,inc.$1K
- Sun Pharmaceutical Industries Inc.$394
- Aerie Pharmaceuticals, Inc.$333
- Bausch & Lomb, A Division Of Bausch Health US, LLC$206
- plus $1K from 16 others
Across 9 payments — averaging $3342.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$30K
What the payments were for
- Consulting fees$1,30017%
- Food & beverage$6,30183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 119 | $3,174 |
| Alcon | 42 | $1,258 |
| NEW World Medical,inc. | 18 | $1,030 |
| Sun Pharmaceutical Industries Inc. | 22 | $394 |
| Aerie Pharmaceuticals, Inc. | 16 | $333 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $206 |
| Oyster Point Pharma, Inc. | 8 | $197 |
| Kala Pharmaceuticals, Inc. | 13 | $175 |
| Bausch & Lomb Americas Inc. | 4 | $153 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $139 |
| Novartis | 7 | $132 |
| Rayner Intraocular Lenses Limited | 3 | $71 |
| Thea Pharma Inc. | 4 | $68 |
| Sight Sciences, Inc. | 3 | $51 |
| Optos, Inc. | 1 | $50 |
| Ocular Therapeutix, Inc. | 2 | $38 |
| Dompe US, Inc. | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Tarsus Pharmaceuticals, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $16 |
| Medline Industries LP | 1 | $13 |
| Iridex Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$671
- Kahook Dual Blade$671
- Clareon PanOptix Pro$141
- Clearpath$141
- Streamline$141
- Rocklatan$140
- LUMIGAN$122
- COMBIGAN$122
- VERITAS Vision System$104
How this compares
$7,601 in reported general payments places this provider in the 85th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 856 | $476,177 |
| CombiganBrimonidine Tartrate/Timolol | 511 | $228,691 |
| RhopressaNetarsudil Mesylate | 243 | $140,415 |
| Alphagan PBrimonidine Tartrate | 242 | $100,299 |
| RocklatanNetarsudil Mesylat/Latanoprost | 142 | $87,186 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 451 | $82,622 |
| VyzultaLatanoprostene Bunod | 122 | $54,699 |
| Latanoprost | 3,728 | $43,377 |
| Brimonidine Tartrate | 700 | $39,481 |
| RestasisCyclosporine | 31 | $30,116 |
| Prednisolone Acetate | 698 | $28,728 |
| TobradexTobramycin/Dexamethasone | 109 | $28,452 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 60 | $19,151 |
| Dorzolamide Hcl | 745 | $15,277 |
| XiidraLifitegrast | 12 | $14,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $3,174 | $835,2831,640 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $333 | $227,601385 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $153 | $69,436134 claims |
| AlconSimbrinza, Azopt | $1,258 | $27,21478 claims |
| NovartisTravatan Z | $132 | $14,69241 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $206 | $3,32811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Poland
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Lawrence SingermanBeachwood$599K
- Darrell WhiteWestlake$587K
- Alice EpitropoulosColumbus$531K
- Amy MillerDayton$526K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.